▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Bukwang Pharmaceutical said on March 14 that it held meetings with some 40 companies to discuss potential license deals for its new therapies and drug pipeline expansion on the sideli...
[THE INVESTOR] Korea’s biotech firm EOflow confirmed that it will float its shares on the tech-heavy KOSDAQ as it gains confidence with its wearable insulin delivery patch device backed by venture c...
[THE INVESTOR] Korea’s biotech firm CrystalGenomics said on March 13 it has signed a distribution contract with Daewoong Pharmaceutical to sell its degenerative arthritis treatment Acelex to small l...
[THE INVESTOR] JW Pharmaceutical said on March 12 that it has developed a tablet-type copycat of Avodart, a treatment for hair loss and enlarged prostate developed by GlaxoSmithKline, to target the ...
[THE INVESTOR] Samsung Bioepis, the new drug development arm of South Korea’s Samsung Group, has launched its Herceptin biosimilar in the UK through its local marketing partner MSD, becoming the fir...
[THE INVESTOR] Three Korean pharma companies -- Yuhan, STCube and Alteogen -- announced this week that they have discovered immune checkpoint target candidates that could be developed into oncology ...
[THE INVESTOR] GC Pharma confirmed on March 8 that it has attained regulatory approval to sell a copy version of Sanofi’s blockbuster insulin Lantus in Korea. GC Pharma -- formerly Green Cross -- p...
[THE INVESTOR] Celltrion has dropped its dual-CEO structure, making Kee Woo-sung sole chief executive and naming Kim Hyoung-ki to head its global marketing arm Celltrion Healthcare to strengthen its...
[THE INVESTOR] Shares of Celltrion and Celltrion Healthcare have dropped more than 6 percent in early trading on March 7 after Temasek Holdings sold its stake in a block deal worth up to 1.1 trillio...
[THE INVESTOR] At least six drug candidates developed by Korean pharmaceutical and biotech companies are looking at possible marketing approval from the US Food and Drug Administration this year. M...
[THE INVESTOR] Huons Global said March 6 that it has completed patient enrollment for phase 3 clinical studies of Hutox, its botulinum toxin used for forehead wrinkle treatment, months ahead of sche...
[THE INVESTOR] SK Biopharmaceuticals, the new drug development unit of South Korea’s telecom-to-energy conglomerate SK Group, is drawing closer to launching its investigational narcolepsy drug in th...
[THE INVESTOR] Daewoong Pharmaceutical said on March 5 that it has launched Samfenet, a copy version of breast cancer therapy Herceptin developed by Samsung Bioepis, in Korea. The release comes abo...
[THE INVESTOR] The Korean unit of US health care firm Baxter International said on March 2 it has named former executive Hyun Dong-wook as its new general manger. Hyun had previously worked in the ...
[THE INVESTOR] The Korea Exchange on March 2 suspended trading of Kyung Nam Pharm shares, putting it under review over the drug maker’s alleged accounting irregularities. The suspension, which will...
EosBLACK platform offers ICO alternative
Contract dispute between Reyon and ViroMed deepens
Schindler claims W300b from Korean government over Hyundai Elevator
30 richest stockholders lose over W10 tr this year
Woori Bank’s net profit jumps 19 percent to 11-year high in H1
Samsung ready for mass production of micro LED displays
Asiana offers extra mileage compensation over meal fiasco
[INTERVIEW] Small-cap index can ‘reduce risk’ as long as qualities are checked
July 22, 2018
![[INTERVIEW] Small-cap index can ‘reduce risk’ as long as qualities are checked](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=152&simg=/content/image/2018/07/22/20180722000182_0.jpg&md=20180722170341)
